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Objective: Proximal attachment failure, often leading to graft migration, is a severe complication of endovascular
aneurysm repair (EVAR). Aortic cuffs have been used to treat proximal attachment failure with mixed results. The Zenith
Renu AAA Ancillary Graft (Cook Inc, Bloomington, Ind) is available in two configurations: converter and main body
extension. Both provide proximal extension with active fixation for the treatment of pre-existing endovascular grafts with
failed or failing proximal fixation or seal in patients who are not surgical candidates. We prospectively compared the
outcomes of patient treatment with these two device configurations.
Methods: From September 2005 to May 2008, a prospective, nonrandomized, postmarket registry was conducted to
collect data from 151 patients treated at 95 institutions for proximal aortic endovascular graft failure using the Renu
graft. Treatment indications included inadequate proximal fixation or seal, for example, migration, and type I and III
endoleak. A total of 136 patients (90%) had migration, 111 (74%) had endoleak, and 94 (62%) had endoleaks and graft
migration. AneuRx grafts were present in 126 patients (83%), of which 89 (59%) were treated with a converter and 62
(41%) with a main body extension. Outcomes using converters vs main body extensions for endoleak rates, changes in
aneurysm size, and ruptures were compared.
Results: Preprocedural demographics between the two groups did not differ significantly. Procedural success rates were
98% for the converter group and 100% for the main body extension group. At a mean follow-up of 12.8  7.5 months,
no type III endoleaks (0%)were identified in the converter group, and five (8%) were identified in the main body extension
group. There were no aneurysm ruptures in patients treated with converters (0%) and three ruptures (5%) in patients
treated with main body extensions. Each patient with aneurysm rupture had been treated with a Renu main body
extension, developed a type III endoleak, and underwent surgical conversion. Two of the three patients died postoper-
atively.
Conclusions: Proximal attachment failure and graft migration are potentially lethal complications of EVAR. Proximal
graft extension using an aortic cuff is the easiest technique for salvaging an endovascular graft. Unfortunately, it has a
predictable failure mode (development of a type III endoleak due to component separation) and is associated with a
significantly higher failure rate than with the use of a converter. EVAR salvage with a converter and a femorofemoral
bypass is a more complex but superior option for endovascular graft salvage. (J Vasc Surg 2010;51:1373-80.)Proximal attachment of endovascular grafts can be
either active (eg, barbs, hooks) or passive (ie, radial force)
with transrenal or infrarenal fixation. Proximal attachment
failure, regardless of the type of attachment, often leads to
graft migration, which is a severe complication of endovas-
cular aneurysm repair (EVAR). It has been described as a
potential complication for all available endovascular grafts,
but the AneuRx endovascular graft (Medtronic Vascular,
Santa Rosa, Calif) has been specifically associated with high
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doi:10.1016/j.jvs.2010.01.081rates of migration due to proximal attachment failure or
late aortic neck enlargement, with a cumulative event rate
of up to 66.7% at 4 years.1
The problem appears to be less with the device itself
than with the importance of proper patient selection. The
4-year migration rate was 42% for patients treated outside
of the indications for use of the AneuRx graft and only 5.8%
for patients treated within the indications for use,2 which is
comparable to the 6.4% 5-year migration rate reported in
the AneuRx Clinical Update.3
Aortic cuffs have been used for treatment of patients
with proximal attachment failure with mixed results.4-9
The AneuRx aortic cuffs were initially used due to their
ready availability. Devices such as the Talent aortic cuffs
(Medtronic Vascular), which include additional transrenal
stents for increased pararenal stability, offered an attractive
alternative with the potential for better results. Early expe-
rience with AneuRx and Talent aortic cuffs suggested pro-
cedural success rates90%,9,10 but there was subsequently
a high failure rate with the development of recurrent prox-
imal attachment failure associated with type I or type III
endoleaks. After 14months of follow-up, AneuRx andTalent
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use basis for AneuRx device salvage) were noted to have an
unexpectedly high failure rate of 26% (6 of 23) for both
types combined, with a 13% (2 of 15) failure rate for the
AneuRx cuffs and a 50% (4 of 8) failure rate for the Talent
cuffs.9 The increased use of aortic cuffs for endograft sal-
vage of multiple devices and these early discouraging results
with attempts at salvage of the AneuRx graft suggest that
prospective data are necessary to better evaluate these de-
vices, as well as other endovascular options, for the salvage
of migrated and failed endovascular grafts.
The Zenith Renu AAA Ancillary Graft (Cook Inc,
Bloomington, Ind), available in converter and main body
extension configurations, is a proximal extension with ac-
tive fixation device for the treatment of pre-existing endo-
vascular grafts with failed or failing proximal fixation or seal
in patients who are not surgical candidates. The main body
extension is a transrenal aortic cuff. The converter, which
also has transrenal fixation, extends into one of the iliac
arteries and requires additional femorofemoral bypass and a
contralateral iliac occluder. The outcomes of patients
treated with these two configurations were compared using
the data from a prospective multicenter registry.
METHODS
Study design. From September 2005 to May 2008, a
prospective, nonrandomized, postmarket registry was con-
ducted to collect data from 151 patients treated at 95
institutions for proximal aortic endovascular graft failure
using the Renu graft. Indications for treatment of poor
proximal fixation were reported by each implanting physi-
cian and included migration (reported as 5 to 10 mm or
10 mm), or major endoleak (type I or III), or both.
Indications for use. The Zenith Renu AAA Ancillary
Graft with the H&L-B One-Shot Introduction System is
Table I. Zenith Renu AAA Ancillary Graft indications for
Indication Converter
Iliac/femoral access Compatible with the required introduc
Proximal fixation 1 Length 37 mm from the lowest ren
the bifurcation of the previously plac
cular graft
2 Diameter 18 mm and 28 mm me
from outer wall to outer wall
3 Angle 60° relative to the long axis
rysm
4 Angle 45° relative to the axis of th
aorta
Distal fixation 1 If used without an iliac leg, distal fixa
within a graft segment of 12 mm in
and 17 mm (1 Cook Z stent) in le
more overlap length preferred
2 If used in combination with an iliac l
fixation site 7.5-20 mm in diameter (
from outer wall to outer wall) and 
length, with 20-30 mm preferred
aThe Zenith Renu AAA Ancillary Graft with the H&L-B One-Shot Introdu
prior endovascular repair of infrarenal abdominal aortic or aortoiliac aneuryindicated for secondary endovascular intervention in pa-tients with prior endovascular repair of infrarenal abdomi-
nal aortic or aortoiliac aneurysms in which the proximal
fixation or seal is inadequate (Table I).
Definitions. Migration after Renu implantation is de-
fined as antegrade or retrograde movement of the Renu
components10 mm relative to anatomic landmarks iden-
tified on the first postoperative computed tomography
scan. Endoleak is defined as contrast-enhanced blood en-
tering the aneurysm sac from around the proximal or distal
end of the graft system (type I), through collateral vessels
(type II), between joints of the graft and extension or
through defects in the graft material (type III), or through
the graft material due to high porosity (type IV).
Device description. The Zenith Renu AAA Ancillary
Graft is available as a tapered component (converter) or as
a straight aortic cuff (main body extension). The grafts are
constructed of full-thickness woven polyester fabric sewn to
self-expanding stainless steel Z-stents with braided polyes-
ter and monofilament polypropylene suture. The grafts are
fully stented to provide stability and the force necessary to
open the graft lumen during deployment. In addition, the
stents provide the necessary attachment and seal of the graft
to the landing zones. The bare suprarenal stent at the
proximal end of the graft contains barbs for additional
fixation of the device. To facilitate fluoroscopic visualiza-
tion of the stent graft, four radiopaque markers are posi-
tioned in a circumferential orientation within 2 mm of the
most proximal aspect of the graft material.
Implantation procedure. Before implantation, all
cases were reviewed by a member of the physician review
committee to assure that the patients met the indications
for use of the device and were anatomically suitable. Op-
tions for treatment were discussed with the treating physi-
cian, but the final device configuration was chosen by the
implanting physician. The Renu device was introduced
Main body extension
ystems Compatible with the required introduction systems
tery to
dovas-
1 Length 43 mm from the lowest renal artery to
the bifurcation of the previously placed endovas-
cular graft
d 2 Diameter 18 mm and 28 mm measured
from outer wall to outer wall
aneu- 3 Angle 60° relative to the long axis of the aneu-
rysm
arenal 4 Angle 45° relative to the axis of the suprarenal
aorta
site
eter
with
1 Distal fixation site within a graft segment of 30
mm in diameter and 17 mm (1 Cook Z stent)
in length, with more overlap length preferred
istal
ured
m in
ystem is indicated for secondary endovascular intervention in patients with
which there is inadequate proximal fixation or seal.usea
tion s
al ar
ed en
asure
of the
e supr
tion
diam
ngth,
eg, d
meas
10 mthrough an exposed common femoral artery. Delivery was
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treatment involved deployment of a Renu converter, femo-
rofemoral bypass was performed to revascularize the con-
tralateral lower extremity, and a contralateral iliac occluder
was implanted, if necessary, to avoid retrograde flow into
the aneurysm sac.
Data collection. Data prospectively collected for the
postmarket registry included information from preopera-
tive evaluations and long-term follow-up visits and evalua-
tions. Long-term data collection is ongoing and will con-
tinue annually for 5 years. At each time point, independent
analysis of available preoperative and follow-up imaging is
performed by the angiographic core lab (Cleveland Clinic,
Cleveland, Ohio). All trial data are collected, organized,
stored, and statistically evaluated by MED Institute Inc
(West Lafayette, Ind). Authors had complete access to the
original trial data. Data for this publication were locked 19
months after the last patient entered the registry, and
evaluations are based on available imaging results.
Statistical analysis. Retrospective statistical analysis
was performed on the prospectively collected data using
SAS 9.1 software (SAS Institute, Inc, Cary, NC). Descrip-
tive data are presented as mean  standard error, with
corresponding confidence intervals and P values. Fisher
exact tests and Kaplan-Meier estimations were performed
where appropriate, and a value of P  .05 was considered
statistically significant.
RESULTS
Available case registration, procedural data, and short-
term follow-up data from the 151 registered cases in the
postmarket registry, as reported through May 1, 2008,
were analyzed. Of 151 cases, 89 (59%) were treated with a
Renu converter and 62 (41%) with a Renu main body
extension (Table II). Patients with an AneuRx device ac-
counted for 126 (83%) of the patients treated. The remain-
ing 25 (17%) were treated with other endovascular devices:
Ancure (Abbot Vascular, Abbot Park, IL), Excluder (W. L.
Gore & Assoc, Flagstaff, Ariz), Fortron (Cordis Endovas-
cular, Warren, NJ), Talent (Vanguard, Boston Scientific,
Nattick, Mass), Lifepath (Baxter, Morton Grove, Ill), Ze-
Table II. Pre-existing grafts treated with Renu
configurationa
Device treated
Converter Main body extension
No. (%) No. (%)
AneuRx 74/126 (58.7) 52/126 (41.3)
Ancure 3/9 (33.3) 6/9 (66.7)
Excluder 6/6 (100) 0/6 (0)
Fortron 0/1 (0) 1/1 (100)
Lifepath 1/1 (100) 0/1 (0)
Talent 2/3 (66.7) 1/3 (33.3)
Vanguard 1/2 (50) 1/2 (50)
Zenith 0/1 (0) 1/1 (100)
Othera 2/2 (100) 0/2 (0)
Total 89 62
aHandmade devices.nith, and homemade.Indications for treatment of poor proximal fixation
were reported by each implanting physician and included
migration (reported as 5 to 10 mm or 10 mm) or major
endoleak (type I or III), or both. Of the 151 patients
treated, 111 (74%) had 138 endoleaks, 136 (90%) had
migration, and 94 (62%) had both endoleaks and migra-
tion. Device integrity failure (eg, stent fracture or breakage,
graft tear, component separation), kink, or occlusion were
reported in conjunction with endoleak or migration in 15
cases. The average time to implantation of the Renu graft
after initial endovascular repair was 43.4  18.7 months.
There was no difference in preprocedural demograph-
ics between patients treated with converters and patients
treated with main body extensions. Morphologic and ana-
tomic characteristics were similar between the two groups,
with the only significant difference in the diameter of the
aorta (P  .02; Tables III and IV). At the time of this
analysis, the mean follow-up was 12.8  7.5 months, and
1-month and 12-month follow-up data were available for
99% and 83% of patients, respectively.
The procedural success rate was 99%; two patients were
converted intraoperatively. One patient with a proximal
type I endoleak, a type II endoleak, and migration of an
AneuRx graft was treated with a Renu converter and
Palmaz stent (Johnson & Johnson Corp, New Brunswick,
NJ). The patient required conversion to open repair due to
rupture of the aortic wall proximal to the Renu device fabric
portion. The patient died during the procedure of subse-
quent hypotension and arrhythmia. A second patient with a
proximal type I endoleak of an AneuRx graft was treated
with a Renu converter. Conversion to open repair was
required for a residual type I endoleak noted on the final
angiogram. No additional components were used with the
Renu converter.
Endoleaks. Before or during treatment with the Renu
graft, 111 patients (74%) were noted to have endoleaks. Of
the 138 endoleaks identified, 94 (68%) were proximal type
I endoleaks, 12 (9%) were distal type I endoleaks, 10 (7%)
were type III endoleaks, 17 (12%) were type II endoleaks,
and 5 (4%) were of unspecified or unknown type. The best
endoleak information available indicated that 93 of the 94
proximal type I endoleaks (99%) were no longer present by
the first follow-up after the Renu device was implanted, and
1 (1%) was persistent. In addition, all previously reported
type III endoleaks had resolved by the 1-month follow-up.
Although four distal type I endoleaks remained at the first
follow-up, three of these were unrelated to the Renu com-
ponent. Additional information has not yet been provided
for the fourth patient.
Proximal type I endoleaks occurred in four patients
(patients 1 to 4 in Table V) after Renu implantation. The
first endoleak was identified preoperatively and persisted
after treatment. The patient’s treatment involved successful
conversion to open repair at 3 months. The second new
proximal type I endoleak was identified at 30 days and
persisted at 12 and 24 months; the patient has not under-
gone any further intervention. The third was identified at
24 months; the patient underwent a successful secondary
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The final new proximal type I endoleak was identified by
the site at 24 months. At the time of the analysis, this
patient had not undergone any secondary procedures. All
of the proximal type I endoleaks were found in patients who
underwent placement of Renu converters and had disad-
Table III. Morphologic characteristics
Characteristics
Converter
Main body
extension
PaNo. (%) No. (%)
Location of aneurysm
Aorta 84 (94.4) 57 (91.9) .74
Right iliac artery 18 (20.2) 11 (17.7) .83
Left iliac artery 8 (9.0) 10 (16.1) .21
Other artery 11 (12.4) 7 (11.3) .59
Plaque/Thrombosis .52
NA 5 (5.6) 5 (8.1)
None (0%-30%) 12 (13.5) 4 (6.5)
Partial (30%-70%) 62 (69.7) 47 (75.8)
Circumferential (70%-100%) 10 (11.2) 6 (9.7)
Neck shape .98
NA 4 (4.5) 4 (6.5)
Funnel 1 (1.1) 1 (1.6)
Inverted funnel 19 (21.4) 12 (19.4)
Irregular 7 (7.9) 5 (8.1)
Parallel 58 (65.2) 40 (64.5)
Right iliac artery status .60
NA 9 (10.1) 7 (11.3)
Occluded 14 (15.7) 13 (21.0)
Patent 62 (69.7) 42 (67.7)
Stenosed 3 (3.4) 0 (0)
Unknown 1 (1.1) 0 (0)
Left iliac artery status .99
NA 10 (11.2) 7 (11.3)
Occluded 9 (10.1) 7 (11.3)
Patent 65 (73.0) 45 (72.6)
Stenosed 4 (4.5) 3 (4.8)
Unknown 1 (1.1) 0 (0)
Right iliac artery tortuosity .71
NA 7 (7.9) 5 (8.1)
None 18 (20.2) 15 (24.2)
Mild 51 (57.3) 37 (59.7)
Moderate 12 (13.5) 4 (6.5)
Severe 1 (1.1) 1 (1.6)
Left iliac artery tortuosity .81
NA 5 (5.6) 6 (9.7)
None 18 (20.2) 15 (24.2)
Mild 52 (58.4) 34 (54.8)
Moderate 12 (13.5) 6 (9.7)
Severe 2 (2.3) 1 (1.6)
Right iliac artery calcification .77
NA 7 (7.9) 6 (9.7)
None 3 (3.4) 4 (6.5)
Mild 67 (75.3) 43 (69.4)
Moderate 12 (13.5) 9 (14.5)
Left iliac artery calcification .77
NA 6 (6.7) 6 (9.7)
None 5 (5.6) 4 (6.5)
Mild 67 (75.3) 42 (67.7)
Moderate 11 (12.4) 10 (16.1)
NA, Not available.
aP values are based on the Fisher exact test.vantaged proximal necks.The 10 type III endoleaks identified before Renu de-
vice implantation were successfully treated with implanta-
tion of 9 Renu converters and 1 Renumain body extension;
however, 5 new (post-Renu device implantation) type III
endoleaks (patients 5-9 in Table V) have been observed
during follow-up. Three of these were noted on follow-up
imaging. Patient 5 had a type III endoleak at 30 days. The
aneurysm ruptured at 12 months, and the patient’s treat-
ment involved successful conversion to open repair. A type
III endoleak was identified at 30 days in patient 6. This
patient’s AAA measured 63 mm at implantation and 75
mm at the time of the endoleak diagnosis. No additional
information was available for this patient. A type III en-
doleak was found in patient 7 during the 24-month follow-up
visit, and a secondary intervention (placement of an addi-
tional Zenith component) was successful. The remaining
two patients with endoleaks were identified when they
presented with ruptured aneurysms. The five patients who
presented with type III endoleaks during follow-up were
originally treated with Renu main body extensions.
There was a significant difference in type III endoleak
rates (P .05), with 0% (0 of 89) for converters and 8% (5
of 62) for main body extensions. A Kaplan-Meier analysis
estimates freedom from type III endoleak as 100% at 24
months in patients implanted with a Renu converter and
92% in patients implanted with a main body extension
(Fig 1).
Aneurysm size. Physicians were asked to provide in-
formation regarding aneurysm enlargement (5 mm),
contraction (5 mm), or stabilization (5 mm enlarge-
ment or contraction) at each follow-up period. In the
converter group, 95% (62 of 65) of AAAs stabilized or
contracted by 12 months and 96% (24 of 25) by 24
months. In the main body extension group, 91% (30 of 33)
of AAAs stabilized or contracted by 12 months and 70% (7
of 10) by 24 months. Although the percentages of aneu-
rysms that contracted or stabilized are somewhat higher at
each follow-up in the converter group than in the main body
extension group, these results are not statistically significant
(Table VI). A Kaplan-Meier analysis estimates freedom from
physician-reported aneurysm growth at 24 months as 85.4%
in patients implanted with a Renu converter and 85.5% in
patients implanted with a main body extension (Fig 2).
Aneurysm rupture. Three aneurysm ruptures after
Renu implantation were identified in patients who received
Renumain body extensions and had type III endoleaks that
were identified at follow-up imaging or at the time of
emergency conversion to open repair. Although the differ-
ence in aneurysm rupture is not statistically significant (P
.067), it is clinically significant, with 0% (0 of 89) for
converters and 5% (3 of 62) for main body extensions. A
Kaplan-Meier analysis estimates freedom from rupture as
100% at 24 months in patients implanted with a Renu
converter and 95.2% in patients implanted with a main
body extension (Fig 3). The three patients with ruptured
aneurysms were subsequently treated with open surgical
repair. One patient underwent graft conversion at 12
months after Renu device implantation and recovered; the
roxim
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procedure (12 months and 16 months after Renu implan-
tation). A Kaplan-Meier analysis estimates freedom from
conversion as 96.6% at 24 months in patients implanted
with a Renu converter and 98.4% in patients implanted
with a main body extension (Fig 4).
DISCUSSION
The ideal way to manage endograft migration depends
on many factors. Our review of the Renu registry data
suggests that although placement of a proximal cuff can be
an immediately successful technique for endovascular graft
salvage, there is an increased risk that component discon-
nection will develop. This exposes the patient to an in-
Table IV. Anatomic characteristics
Characteristics Converter No.
Aortic aneurysm diameter, mm 68.3  16.6 89
Right iliac aneurysm diameter, mm 37.8  11.4 19
Left iliac aneurysm diameter, mm 52.9  23.2 8
Other aneurysm diameter, mm 29.3  14.5 11
Distance from lowest patent renal
artery to proximal aspect of the
pre-existing graft, mm 17.8  16.1 88
Distance from lowest patent renal
artery to bifurcation of pre-
existing graft, mm 62.4  23.7 85
Diameter of aortic neck
immediately below lowest renal
artery, mm 27.3  6.1 88
Diameter of aortic neck
immediately above lowest renal
artery, mm 33.4  12.6 88
Diameter of aortic neck 10 mm
below lowest renal artery, mm 29.4  5.5 88
Diameter of aortic neck 15 mm
below lowest renal artery, mm 31.5  5.6 88
Suprarenal to infrarenal neck
angulation, degrees 28.6  15.7 79
Neck angle relative to long axis of
aneurysm, degrees 48.4  21.8 78
aConfidence interval (CI) on difference in means for continuous variables a
bP values are based on the Fisher exact test.
cStatistically significant.
Table V. Summary of select patients with endoleaks
Pt Configuration Diagnosis
1 Converter Pre-op/peri-op
2 Converter 30 days (present at 12 & 24 m
3 Converter 24 mon
4 Converter 24 mon
5 Main body extension 30 days
6 Main body extension 30 days
7 Main body extension 24 mon
8 Main body extension Rupture at 12 mon
9 Main body extension Rupture at 16 mon
aAt time of data lock, there had been no interventions. Since that time, th
months, and conversion to open surgical repair at 30 months to treat the pcreased risk of aneurysm rupture when compared withsalvage using a converter. EVAR was first described by
Parodi11 in 1991; since then, it has been embraced as a
minimally invasive alternative to open AAA repair in pa-
tients with suitable anatomy. Because of lower rates of
operative mortality and severe perioperative complications,
the option of local anesthesia, and faster recovery times,
EVARmay be the preferred intervention for many patients.
Appropriate patient selection (based on United States pro-
spective studies of different devices), coupled with accurate
graft deployment, can lead to mortality rates of 2%, and
freedom from aneurysm rupture, aneurysm-related deaths,
and conversion 95%.12-14
Since the inception of EVAR, the safety, effectiveness,
and durability of endovascular grafts have been widely
Main body extension No. CIa Pb
62.2  13.3 60 0.93, 11.36 .02c
35.3  9.2 11 5.79, 10.91 .53
37.4  6.0 10 4.05, 35.00 .10
18.9  4.7 7 0.26, 20.57 .05
18.4  11.6 61 5.29, 3.93 .77
61.1  17.7 59 5.67, 8.37 .70
26.3  3.9 60 0.68, 2.66 .24
32.7  8.1 60 2.75, 4.16 .69
29.2  4.8 60 1.58, 1.96 .83
32.0  6.7 60 2.64, 1.50 .59
23.4  13.8 54 0.13, 10.64 .06
41.2  17.3 53 0.08, 14.52 .05
ference in percentages for categoric variables.
Endoleak Outcome
Proximal type I Converted to open repair at 3 mon
Proximal type I No further intervention noted
Proximal type I Resolved after intervention
Proximal type I No intervention
Type III Ruptured, converted to open repair
Type III No interventiona (63 mm¡ 75 mm)
Type III Resolved after intervention
Type III Died
Type III Died
ent has undergone coil embolization at 25 months, stent placement at 29
al type I endoleak.nd difon)
e patidebated, and EVAR has its own unique set of potential
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regarding the long-term outcomes of EVAR is the potential
for caudal graft migration and proximal attachment failure
that can lead to lethal complications. Despite best efforts,
proximal attachment failure is one of the most common
indications for secondary interventions15 and may lead to
migration, subsequent endoleak, and aneurysm rupture.
Migration, with rates ranging from 5% to 42% for AneuRx
devices,2 has associated complications such as challenging
proximal neck anatomy, poor iliac fixation, and suboptimal
graft deployment. Although reported migration rates for
other devices are lower,16 each has device-specific factors
that influence migration. Improvements in patient selec-
tion, technically accurate deployment of available devices,
and new, more flexible devices will diminish the rate of
distal graft migration and proximal attachment failure.
Secondary procedures to treat migration and proximal
attachment failure are often performed 1 year after the
initial EVAR, with large series reporting secondary inter-
ventions at an average of 14 and 18 months.5,15 Many
patients originally treated endoluminally are unfit for con-
ventional open surgical treatment due to cardiovascular,
pulmonary, or other physiologic problems. Open repair in
these patients can lead to high rates of acute morbidity and
mortality.17 Failing to treat an enlarging aneurysm will
eventually result in rupture, necessitating treatment despite
a high probability of death. Thus, a secondary endovascular
intervention may be the best option for many of these
patients.
Aortic main body extension cuffs, with or without
transrenal stents, have been used as an alternative to open
surgical repair for the endovascular salvage of failed grafts.
The stability of the new reconstruction, which includes an
aortic cuff and a distorted, migrated endovascular graft,
depends on the overlap, apposition, and friction seal be-
tween components to prevent separation. Many devices,
Fig 1. Kaplan-Meier of freedom from type III endoleak in pa-
tients implanted with a Renu graft.including the original AneuRx, AneuRx Advantage, Talent,and Excluder grafts, have short main bodies that allow for
only limited, suboptimal component overlap. In addition,
angulation and poor anatomy often preclude optimal com-
ponent overlap and appropriate apposition. Small multi-
center series suggested high recurrent failure rates,9 but
these results had not been validated in larger retrospective
or prospective series until now. Although proximal exten-
sion using an aortic cuff is the simplest technique for
endovascular graft salvage, early results from the current
Renu registry indicate that there is an increased risk
of developing component disconnection and type III
endoleak—and potential aneurysm rupture—when com-
pared with salvage using a converter. Furthermore, pro-
gression of disease challenges successful reconstruction ef-
forts.
When an aortic cuff is the best treatment for a specific
patient, additional procedures to secure the components
together should be considered. Large balloon-expandable
stents have been used in selected cases to increase the force
needed to separate the components and improve the seal
between them.18,19 Ancillary devices that deploy staples to
secure endovascular grafts to the aortic wall may be useful
to secure endovascular graft components together.
The Aptus endovascular graft (Aptus Endosystems,
Sunnyvale, Calif), which is currently completing a phase II
trial, has a unique proximal attachment system that uses
multiple, single-deployment, spiral nitinol staples that se-
cure the device to the aortic wall. However, these staples
can only be used with polyester grafts due to the tendency
of polytetrafluoroethylene to tear with any perforations. A
staple system may be useful in the future to secure endo-
vascular components together.
The registry results to date indicate that the Renu
converter is the best currently available reconstruction op-
tion for treatment of most patients with proximal attach-
ment failure and caudal graft migration. The device has a
stable transrenal attachment with active fixation that has
been associated with very lowmigration rates (0%10 mm
for the Zenith device at 5 years),12 a proximal sealing stent
designed to seal type I endoleaks and maintain proximal
seal, as well as excellent distal attachment, seal, and overlap
into a stable limb of the failed initial endovascular graft or
the iliac artery distally. The device has had excellent 12-
month results with aneurysm stability or contraction in 95%
of the patients treated, freedom from aneurysm-related
death of 100%, and freedom from conversion of 97% de-
spite the challenging anatomies treated.
Although the Renu converter does require additional
procedures, including contralateral iliac occlusion and
femorofemoral bypass, the need for femorofemoral bypass
with the converter should not raise concerns regarding
patency. The reported patency rates are only 60% to 80% for
patients with occlusive disease,20-23 but are 91% to 100%
for patients with aneurysmal disease.20,24-27 The difference
in patency rates is attributed to the idea that patients with
aneurysmal disease have little or no peripheral occlusive
disease.
JOURNAL OF VASCULAR SURGERY
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struction with a new bifurcated graft is the best treatment
option: it provides seal and stability with proximal and
Fig 2. Kaplan-Meier of freedom from aneurysm growth in pa-
tients implanted with a Renu graft.
Fig 3. Kaplan-Meier of freedom from rupture in patients im-
planted with a Renu graft.
Table VI. Change in aneurysm size by Renu configuratio
Aneurysm change
12-month follow-up
Converter Main bo
(N  65) (N
Contracted (5 mm) 19
Expanded (5 mm) 3b
Stabilized 43
aImaging is not available for two patients.
bA proximal type I endoleak was reported for one patient, a type II endoleak was r
cA type II endoleak was reported for two patients. No endoleak was reporte
dA proximal Type I endoleak was reported for this patient.
eEndoleak status is unknown for this case.distal fixation points, avoids the need for additional femo-rofemoral bypass, and maintains a bifurcated reconstruc-
tion. Unfortunately, this procedure can be technically chal-
lenging and can only be performed in those few patients
who have a reasonably sized infrarenal neck with 70 mm
of length from the lowest renal artery to the bifurcation of
the migrated graft to accommodate the new endovascular
graft. Currently, all available modular endovascular grafts
are between 70mm (Gore Excluder) and 80mm in covered
length from the top to the bottom of the contralateral leg;
because of these issues, reconstruction with a new bifur-
cated graft is not a procedure often performed.
Limitations. This registry is not designed to provide
information 5 years postprocedure and is still in the data
collection phase. The registry has no control group; there-
fore, comparison with alternative treatment is not an aim of
this registry.
CONCLUSIONS
Proximal endovascular graft extension using an aortic
cuff is the easiest technique for endovascular graft salvage.
However, results of this registry indicate that there is an
increased risk of developing a type III endoleak and poten-
tial aneurysm rupture when compared with the use of a
24-month follow-up
tension Converter Main body extensiona
) (N  25) (N  10)
9 1
1d 1e
15 6
for the second patient, and no endoleak was reported for the third patient.
the third patient.
Fig 4. Kaplan-Meier of freedom from conversion in patients im-
planted with a Renu graft.n
dy ex
 33
3
3c
27
eported
d forconverter. Consideration should also be given to factors
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June 20101380 Thomas et althat may contribute to long-term component separation
(component overlap, angulation, seal, and apposition). Fur-
thermore, if an aortic cuff is determined to be the best treat-
ment option, the additional use of a balloon-expandable stent
should be considered. Results of this prospective registry
indicate that patients with proximal attachment failure
should be considered for a more complex procedure using
a converter and femorofemoral bypass because this second-
ary reconstruction will be more durable than an aortic cuff.
Future endovascular alternatives may help to prevent and
better treat this life-threatening complication of EVAR.
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